PRLD
Prelude Therapeutics Inc
Prelude Therapeutics Inc (PRLD) has 3 SEC Form 4 filings (5 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Apr 28, 2026.
Insiders have net bought $25.0M over the trailing 6 months. The largest single insider purchase in this window was $12.5M by Director, 10% Owner ORBIMED ADVISORS LLC on Apr 21, 2026.
- Industry:Biotechnology
- CEO:Krishna Vaddi
- Employees:79
- HQ:Wilmington, DE, US
- IPO:2020-09-25
Insider Buying
$25.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$313.0M
Price slightly stale
| Source | ||||||
|---|---|---|---|---|---|---|
| Director, 10% Owner | Purchase | 2,815,315 | $12.5M | Apr 23 | SEC ↗ | |
Bonita David PFirst filing | Director, 10% Owner | Purchase | 2,815,315 | $12.5M | Apr 23 | SEC ↗ |
Related companies
Prelude Therapeutics Inc is in the Healthcare sector.